Rising Incidence of Kidney Diseases to Drive the Global Renal Biomarker Market

Global renal biomarker market is anticipated to grow at a CAGR of 7.6% during the forecast period (2024–2031). The increasing incidence of kidney diseases and multiple co-morbidities has driven the demand for renal biomarker market.  Additionally, increasing incidence of chronic diseases such as high blood pressure, diabetes, and obesity also boosts market demand. Furthermore, growing R&D investments will further drive the market growth, as renal biomarkers are generally used in preclinical and clinical trials, to assess the safety of new drugs. 

Acute Kidney Injury (AKI) and chronic kidney disease (CKD) significantly increase morbidity and mortality, prompting researchers to develop diagnostic procedures using surrogate markers such as Serum Creatinine (SCr) for early detection. The demand for innovative techniques in the medical sector is driving market growth, with government organizations focusing on non-invasive biomarker processes. Additionally, the expansion of research centers is propelling the market forward. The year-over-year increase in cardiovascular diseases, CKD, and diabetes significantly contributes to market development. Increasing R&D activities and the rising diagnostic applications of biomarkers are expected to enhance market growth further. The proliferation of Contract Research Organizations (CROs) is also favoring market expansion. 

Browse the full report description of “Renal Biomarker Market Size, Share & Trends Analysis Report By Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, and Pharmacodynamic Biomarkers), by Diagnostic Technique (Elisa, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle, and Enhanced Turbidimetric Immunoassay), and by End-User (Hospitals, Diagnostic Labs, and Research Centres) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/renal-biomarker-market

However, the current biomarkers lack specificity and fail to target particular diseases, making it difficult to detect certain conditions. This inadequacy, particularly in detecting acute and chronic kidney diseases, is a significant barrier to the growth of the renal biomarkers market. The absence of effective detection methods for these kidney conditions is a primary factor limiting market expansion. Additionally, inadequate reimbursement policies further impede market demand. The use of inconsistent and substandard quality markers is expected to hinder market growth in Europe. Regulatory hurdles and the substantial costs associated with drug discovery, development, and implementation also pose significant challenges to market growth.

In 2023, the Enzyme-Linked Immunosorbent Assay (ELISA) segment led the renal biomarkers market. This dominance is expected to continue throughout the forecast period, driven by the rising demand for quality healthcare services. ELISA is a popular choice for renal biomarker analysis owing to its high sensitivity and specificity in identifying biological samples. Its adaptability and reliability further cement its leading position by meeting the diagnostic needs of both researchers and medical practitioners. Additionally, the increasing incidence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, and the emphasis on early diagnosis are contributing to the growth of this segment. The surge in chronic disease prevalence has significantly boosted the demand for ELISA.

North America currently dominates the renal biomarkers market, with the United States holding the largest share attributing to a significant increase in FDA approvals for molecular biomarkers over the past decade. The rising prevalence of chronic kidney disorders and an aging population in the US drive demand for renal biomarkers. Government initiatives, such as the National Institute of Standards and Technology's development of a precise albumin measurement standard, and strategic activities by market players, such as Aravive Inc.'s positive trial results for batiraxcept, further boost market growth. Additionally, in January 2024, LifeLabs partnered with Klinrisk to enhance early detection and treatment of chronic kidney disease through their innovative Klinrisk Score.

Recent Developments

• In January 2024, the University of Houston lab developed new biomarkers for earlier diagnosis of lupus nephritis, significantly enhancing diagnostic accuracy. The research identified at least six new urine biomarkers for active renal lupus, validated across patients from diverse ethnic backgrounds.

• In November 2023, Chinese researchers announced that urinary biomarkers demonstrated improved performance in disease detection compared to plasma biomarkers, proving more effective than their serum counterparts. This method offers a simple and non-invasive urine collection process.

• In September 2023, researchers identified a novel urinary biomarker for early diagnosis of renal failure. The study examined over 1,200 diabetic patients with weakened or damaged kidneys, revealing that higher urine levels of adenine correlate with increased rates of renal damage or failure.

• In January 2023, Renalytix PLC introduced PRIME-CKD, a project aimed at validating and implementing their product in clinical practice. PRIME-CKD also involves developing novel biomarker-based tests to predict how patients with chronic kidney disease (CKD) will respond to existing medications.

Market Coverage  

· The market number available for 2023-2031 

· Base year: 2023 

· Forecast period: 2024-2031 

· Segment Covered- 

o By Type

o By Diagnostic Technique

o By End-Users

· Regions Covered- 

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World

• Competitive Landscape: Abbott Laboratories, F. Hoffmann-La Roche Ltd., Randox Laboratories Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc., among others.

Key questions addressed by the report 

• What is the market's growth rate? 
• Which segment and region dominate the market in the base year? 
• Which segment and region will project the fastest growth in the market? 
• Who is the leader in the market? 
• How are players addressing challenges to sustain growth? 
• Where is the investment opportunity? 

Global Renal Biomarker Market Report Segment 

By Type

• Diagnostic Biomarkers
• Prognostic Biomarkers
• Predictive Biomarkers
• Pharmacodynamic Biomarkers

By Diagnostic Technique

• Elisa
• Colorimetric Assay
• Liquid Chromatography-Mass Spectrometry
• Particle-Enhanced Turbidimetric Immunoassay

By End-User

• Hospitals
• Diagnostic Labs
• Research Centers

Global Renal Biomarker Market Report Segment by Region 

North America 

· United States 

· Canada 

Europe 

· UK 

· Germany 

· Italy 

· Spain 

· France 

· Rest of Europe 

Asia-Pacific 

· China 

· India 

· Japan 

· South Korea 

· Rest of Asia-Pacific 

Rest of the World 

· Latin America

· Middle East and Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/renal-biomarker-market